Active SU(1,1) atom interferometry

Autor: Linnemann, D., Schulz, J., Muessel, W., Kunkel, P., Prüfer, M., Frölian, A., Strobel, H., Oberthaler, M. K.

Publikováno v: Quantum Science and Technology 2, 044009 (2017)

Active interferometers use amplifying elements for beam splitting and recombination. We experimentally implement such a device by using spin exchange in a Bose-Einstein condensate. The two interferometry modes are initially empty spin states that get

Externí odkaz: http://arxiv.org/abs/1711.04552

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.

Autor: Kiefer A; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany.; Frankfurt Cancer Institute, Goethe University, 60590 Frankfurt, Germany., Prüfer M; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany., Röder J; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany.; Frankfurt Cancer Institute, Goethe University, 60590 Frankfurt, Germany., Pfeifer Serrahima J; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany.; Frankfurt Cancer Institute, Goethe University, 60590 Frankfurt, Germany., Bodden M; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany., Kühnel I; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany., Oberoi P; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany., Wels WS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, 60596 Frankfurt, Germany.; Frankfurt Cancer Institute, Goethe University, 60590 Frankfurt, Germany.; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, a Partnership between DKFZ and University Hospital Frankfurt, 60590 Frankfurt, Germany.

Publikováno v: Cells [Cells] 2024 Jan 28; Vol. 13 (3). Date of Electronic Publication: 2024 Jan 28.

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers.

Autor: Pfeifer Serrahima J; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Zhang C; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany.; Partner Site Frankfurt/Mainz, German Cancer Consortium (DKTK), Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Oberoi P; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany.; Partner Site Frankfurt/Mainz, German Cancer Consortium (DKTK), Frankfurt, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Bodden M; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Röder J; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany.; Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany., Arndt C; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Feldmann A; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany., Kiefer A; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Prüfer M; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Kühnel I; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany., Tonn T; Experimental Transfusion Medicine, Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany.; Partner Site Dresden, German Cancer Consortium (DKTK), Dresden, Germany.; Institute for Transfusion Medicine, German Red Cross Blood Donation Service North-East, Dresden, Germany., Bachmann M; Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.; Partner Site Dresden, German Cancer Consortium (DKTK), Dresden, Germany.; National Center for Tumor Diseases (NCT) and Tumor Immunology, University Cancer Center (UCC) Carl Gustav Carus, TU Dresden, Dresden, Germany., Wels WS; Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Paul-Ehrlich-Straße 42-44, 60596, Frankfurt, Germany. wels@gsh.uni-frankfurt.de.; Partner Site Frankfurt/Mainz, German Cancer Consortium (DKTK), Frankfurt, Germany. wels@gsh.uni-frankfurt.de.; German Cancer Research Center (DKFZ), Heidelberg, Germany. wels@gsh.uni-frankfurt.de.; Frankfurt Cancer Institute, Goethe University, Frankfurt, Germany. wels@gsh.uni-frankfurt.de.

Publikováno v: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Sep; Vol. 72 (9), pp. 2905-2918. Date of Electronic Publication: 2023 Jan 23.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.